Objective To introduce the general testing methods for glass materials and containers for pharmaceutical packaging within the packaging material standard system in the 2025 Edition of the Chinese Pharmacopoeia,aiming to provide assistance for the implementation of these standards.Methods Introduce the general situation of the revision of general testing methods for glass materials and containers for pharmaceutical use.The improvement of new general testing method standards is summarized by contrasting the new version of the general testing methods for pharmaceutical glass materials and containers with the current standards.Results The general testing methods for pharmaceutical glass materials and containers in the Chinese Pharmacopoeia 2025 Edition are more scientific in structure,more rational and operational.Conclusion The 11 general testing methods will control the quality of pharmaceutical glass materials and containers,which could contribute to the enhancement of the quality and efficacy of drugs in our country.

Objective Interpret the method of determining the shading property for colored glass containers in the Chinese Pharmacopoeia(2025 edition)in detail,and provide theoretical guidance and technical support for the implementation of standards.Methods By summarizing and analyzing the related abroad standards for shading property of colored glass containers,combining with the results of experimental verification,the method for determining the shading property of colored glass containers was established in accordance with the requirements of the construction of the pharmaceutical packaging material system in the Chinese Pharmacopoeia.An explanation was provided for the selection of instruments and equipment,the requirements for the preparation of the samples,and the way of expressing the results.Results The method of determining the shading property for colored glass containers,formulated in conjunction with international standards,proposed scientifically reasonable operational requirements based on solid experimental verification data,and solved the problem of having no"method"to follow in the domestic shading property measurement.Conclusion The proposal of the method for determining the shading property of colored glass containers filled the industry gap,improved the pharmaceutical packaging material standard system,standardized the method operation,and was conducive to promoting industrial development and ensuring the safety of formulations.

Objective:To compare the efficacies of endovascular therapy (EVT) and standard medical therapy in acute ischemic stroke (AIS) patients aged ≥85 years, and analyze the independent influencing factors for poor prognosis of AIS patients after EVT.Methods:Sixty-nine AIS patients aged ≥85 years admitted to Department of Neurology, Xi'an Third Hospital from January 2018 to April 2024, including 40 accepted EVT and 28 accepted standard medicinal therapy, were enrolled. Modified Rankin scale (mRS) was used to evaluate the prognosis of the patients 90 days after onset. General data, prognosis and complications between the EVT group and standard medical therapy group were compared. General data, treatment processes and complications between patients with good prognosis and poor prognosis in the EVT group were compared. Multivariate Logistic regression was used to analyze the independent influencing factors for poor prognosis in AIS patients after EVT.Results:Compared with the standard medical therapy, the EVT group had significantly lower NIHSS score at discharge, greater improvement in NIHSS score (NIHSS score at admission-NIHSS score at discharge), lower mRS score 90 days after onset, higher good prognosis rate, lower mortality rate within 90 days of onset, and longer hospital stay ( P<0.05). In the EVT group, 11 patients (27.5%) had good prognosis and 29 patients (72.5%) had poor prognosis 90 days after onset. Compared with the good prognosis group, the poor prognosis group had significantly higher blood glucose level and lower Alberta Stroke Program Early CT Score (ASPECT) on admission ( P<0.05). Multivariate Logistic regression analysis showed that blood glucose on admission ( OR=2.363, 95% CI: 1.134-4.928, P=0.022) and ASPECT score on admission ( OR=0.273, 95% CI: 0.088-0.854, P=0.026) were independent influencing factors for poor prognosis in AIS patients after EVT. Conclusion:AIS patients aged ≥85 years received EVT have better prognosis compared with those accepted standard medical therapy; these patients with high glucose level and low ASPECT score on admission have poor prognosis.

Objective To explore the influence of the chronic disease management model based on wearable devices on the self-management ability,quality of life and physiological index control of patients after percutaneous coronary intervention(PCI).Methods Eighty patients with coronary heart disease who underwent PCI in Hefei BOE Hospital from April to September 2024 were selected as research objects.They were divided into control group and intervention group according to the random number table method,with 40 cases in each group.The control group received the conventional care model,while the intervention group adopted a postoperative chronic disease management model based on wearable devices,and the intervention period was 6 months for all.The coronary artery disease self-management scale(CSMS)was used to assess self-management ability,and the Seattle angina questionnaire(SAQ)was used to assess quality of life before and after the intervention.Additionally,the compliance rates of blood pressure,low density lipoprotein-cholesterol(LDL-C),and body mass index(BMI)were recorded.Results After the intervention,the scores of each dimension and total score of CSMS,as well as the scores of each dimension of SAQ of two groups of patients were significantly higher than those before the intervention(P＜0.05).Moreover,the scores of each dimension and total score of CSMS and the scores of each dimension of SAQ of intervention group were significantly higher than those of control group(P＜0.05).The compliance rates of blood pressure,LDL-C and BMI in intervention group were significantly higher than those in control group(P＜0.05).Conclusion The chronic disease management model based on wearable devices,through data monitoring,team collaboration and dynamic intervention,can significantly enhance the self-management ability of patients after PCI,improve their quality of life and the compliance rate of key physiological indicators,and has clinical promotion value.

Objective To introduce the general testing methods for glass materials and containers for pharmaceutical packaging within the packaging material standard system in the 2025 Edition of the Chinese Pharmacopoeia,aiming to provide assistance for the implementation of these standards.Methods Introduce the general situation of the revision of general testing methods for glass materials and containers for pharmaceutical use.The improvement of new general testing method standards is summarized by contrasting the new version of the general testing methods for pharmaceutical glass materials and containers with the current standards.Results The general testing methods for pharmaceutical glass materials and containers in the Chinese Pharmacopoeia 2025 Edition are more scientific in structure,more rational and operational.Conclusion The 11 general testing methods will control the quality of pharmaceutical glass materials and containers,which could contribute to the enhancement of the quality and efficacy of drugs in our country.

Objective Interpret the method of determining the shading property for colored glass containers in the Chinese Pharmacopoeia(2025 edition)in detail,and provide theoretical guidance and technical support for the implementation of standards.Methods By summarizing and analyzing the related abroad standards for shading property of colored glass containers,combining with the results of experimental verification,the method for determining the shading property of colored glass containers was established in accordance with the requirements of the construction of the pharmaceutical packaging material system in the Chinese Pharmacopoeia.An explanation was provided for the selection of instruments and equipment,the requirements for the preparation of the samples,and the way of expressing the results.Results The method of determining the shading property for colored glass containers,formulated in conjunction with international standards,proposed scientifically reasonable operational requirements based on solid experimental verification data,and solved the problem of having no"method"to follow in the domestic shading property measurement.Conclusion The proposal of the method for determining the shading property of colored glass containers filled the industry gap,improved the pharmaceutical packaging material standard system,standardized the method operation,and was conducive to promoting industrial development and ensuring the safety of formulations.

Objective To explore the influence of the chronic disease management model based on wearable devices on the self-management ability,quality of life and physiological index control of patients after percutaneous coronary intervention(PCI).Methods Eighty patients with coronary heart disease who underwent PCI in Hefei BOE Hospital from April to September 2024 were selected as research objects.They were divided into control group and intervention group according to the random number table method,with 40 cases in each group.The control group received the conventional care model,while the intervention group adopted a postoperative chronic disease management model based on wearable devices,and the intervention period was 6 months for all.The coronary artery disease self-management scale(CSMS)was used to assess self-management ability,and the Seattle angina questionnaire(SAQ)was used to assess quality of life before and after the intervention.Additionally,the compliance rates of blood pressure,low density lipoprotein-cholesterol(LDL-C),and body mass index(BMI)were recorded.Results After the intervention,the scores of each dimension and total score of CSMS,as well as the scores of each dimension of SAQ of two groups of patients were significantly higher than those before the intervention(P＜0.05).Moreover,the scores of each dimension and total score of CSMS and the scores of each dimension of SAQ of intervention group were significantly higher than those of control group(P＜0.05).The compliance rates of blood pressure,LDL-C and BMI in intervention group were significantly higher than those in control group(P＜0.05).Conclusion The chronic disease management model based on wearable devices,through data monitoring,team collaboration and dynamic intervention,can significantly enhance the self-management ability of patients after PCI,improve their quality of life and the compliance rate of key physiological indicators,and has clinical promotion value.

Objective:To compare the efficacies of endovascular therapy (EVT) and standard medical therapy in acute ischemic stroke (AIS) patients aged ≥85 years, and analyze the independent influencing factors for poor prognosis of AIS patients after EVT.Methods:Sixty-nine AIS patients aged ≥85 years admitted to Department of Neurology, Xi'an Third Hospital from January 2018 to April 2024, including 40 accepted EVT and 28 accepted standard medicinal therapy, were enrolled. Modified Rankin scale (mRS) was used to evaluate the prognosis of the patients 90 days after onset. General data, prognosis and complications between the EVT group and standard medical therapy group were compared. General data, treatment processes and complications between patients with good prognosis and poor prognosis in the EVT group were compared. Multivariate Logistic regression was used to analyze the independent influencing factors for poor prognosis in AIS patients after EVT.Results:Compared with the standard medical therapy, the EVT group had significantly lower NIHSS score at discharge, greater improvement in NIHSS score (NIHSS score at admission-NIHSS score at discharge), lower mRS score 90 days after onset, higher good prognosis rate, lower mortality rate within 90 days of onset, and longer hospital stay ( P<0.05). In the EVT group, 11 patients (27.5%) had good prognosis and 29 patients (72.5%) had poor prognosis 90 days after onset. Compared with the good prognosis group, the poor prognosis group had significantly higher blood glucose level and lower Alberta Stroke Program Early CT Score (ASPECT) on admission ( P<0.05). Multivariate Logistic regression analysis showed that blood glucose on admission ( OR=2.363, 95% CI: 1.134-4.928, P=0.022) and ASPECT score on admission ( OR=0.273, 95% CI: 0.088-0.854, P=0.026) were independent influencing factors for poor prognosis in AIS patients after EVT. Conclusion:AIS patients aged ≥85 years received EVT have better prognosis compared with those accepted standard medical therapy; these patients with high glucose level and low ASPECT score on admission have poor prognosis.

Objective:To evaluate the effect of sevoflurane on Ca 2+ transporter expression in cardiomyocytes during right ventricular remodeling in rats with pulmonary arterial hypertension. Methods:Twenty-four clean-grade healthy male Sprague-Dawley rats, aged 8-10 weeks, weighing 200-250 g, were divided into 4 groups ( n=6 each) by the random number table method: control group (CM group), sevoflurane group (CS group), monocrotaline group (M group) and sevoflurane + monocrotaline group (S group). Monocrotaline 60 mg/kg was intraperitoneally injected in group M and group S, and monocrotaline lysate was intraperitoneally injected in group CM. The rats in S and CS groups inhaled 2.5% sevoflurane for 1 h, twice a week, at an interval of 3 days starting from the first day after injection of monocrotaline. Pulmonary artery acceleration time and pulmonary artery ejection time were measured by transthoracic echocardiography at 6 weeks after monocrotaline injection. The chest was exposed under 3% sevoflurane anesthesia, the heart was perfused, and the pulmonary artery branch and right ventricular myocardial tissues were retained. The wall thickness of pulmonary arterioles and cross-section area of right ventricular cardiomyocytes were observed by HE staining. The expression of Ca 2+ transporter in right ventricular cardiomyocytes was detected by Western blot. Results:Compared with CM group, the ratio of pulmonary artery acceleration time to pulmonary artery ejection time was significantly decreased, the cross-section area of right ventricular cardiomyocytes was increased, the wall thickness of pulmonary arteriole was increased, the expression of type 1 sodium-calcium exchange and inositol triphosphate receptor was up-regulated, and the expression of voltage-dependent L-type calcium channel α1C subunit, type 2 ryanodine receptor, sarcoplasmic reticulum calcium pump 2α and proteinphilin-2 was down-regulated in M group ( P<0.01). Compared with group M, the ratio of pulmonary artery acceleration time to pulmonary artery ejection time was significantly increased, the cross-section area of right ventricular cardiomyocytes was decreased, the wall thickness of pulmonary arteriole was decreased, the expression of type 1 sodium-calcium exchange and inositol triphosphate receptor was down-regulated, and the expression of voltage-dependent L-type calcium channel α1C subunit, type 2 ryanodine receptor, sarcoplasmic reticulum calcium pump 2α and proteinphilin-2 was up-regulated in group S ( P<0.01). Conclusions:The mechanism by which sevoflurane improves right ventricular remodeling is related to regulating the expression of Ca 2+ transporter in cardiomyocytes of rats with pulmonary arterial hypertension.

Objective:To analyze and summarize the key points of design and implementation of new drug clinical trials for ankylosing spondylitis.Methods:The platform for drug clinical trial registration and information published on the official website of center for drug review and evaluation of national medical products administration (CDE) was searched to obtain data and classified statistics was conducted then. The Mean±SD and M ( Q1, Q3) were used for quantitative data for statistical description, and the rate, composition or relative ratio of qualitative data were used for statistical description. Results:A total of 23 clinical trials meeting the requirements were screened, among which 19 were biological products included in nine phase Ⅲ clinical trials. Among the four chemical drugs, two were phase Ⅱ clinical trials. One of the clinical trials on AS adopted the 1966 New York classification criteria, accounting for 4%. Nineteen of the trials adopted the1984 New York classification criteria, accounting for 83%. Three other trials adopted unspecified classification criteria, accounting for 13%. In one of these clinical trials, the age of patients included was older than 16 years old, 9 trials were 18 to 65 years old, 6 were 18 years old but without upper limit. In the definition of active AS, 19 trials took BASDAI≥4 as the cut-off value for active disease, and BASDAI, total back pain, spinal pain and morning stiffness were regarded as active disease in 4.Conclusion:The number of dosestic AS clinical trial projects continnes to rise. The 1984 classification criteria is adopted as the classification criteria in clinical trials. The minimum age in the inclusion criteria is 18 years old, there is no upper limit in age for inclusion. Disease activity can be evaluated by BASDAI score, combined with comprehensive indicators such as night-time back pain, global spinal pain and morning stiffness.